Production (Stage)
Amicus Therapeutics, Inc.
FOLD
$6.22
-$0.04-0.64%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 125.25M | 149.71M | 141.52M | 126.67M | 110.40M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 125.25M | 149.71M | 141.52M | 126.67M | 110.40M |
| Cost of Revenue | 11.70M | 14.84M | 13.28M | 11.26M | 13.57M |
| Gross Profit | 113.55M | 134.87M | 128.24M | 115.41M | 96.84M |
| SG&A Expenses | 91.83M | 86.67M | 75.11M | 73.58M | 88.03M |
| Depreciation & Amortization | 1.84M | 2.04M | 2.17M | 2.18M | 2.15M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 133.20M | 133.74M | 116.72M | 111.70M | 132.08M |
| Operating Income | -7.95M | 15.97M | 24.80M | 14.97M | -21.68M |
| Income Before Tax | -18.05M | 7.93M | 6.79M | 108.00K | -43.58M |
| Income Tax Expenses | 3.64M | -6.81M | 13.51M | 15.81M | 4.84M |
| Earnings from Continuing Operations | -21.69M | 14.74M | -6.73M | -15.70M | -48.42M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -21.69M | 14.74M | -6.73M | -15.70M | -48.42M |
| EBIT | -7.95M | 15.97M | 24.80M | 14.97M | -21.68M |
| EBITDA | -6.12M | 18.01M | 26.97M | 17.15M | -19.52M |
| EPS Basic | -0.07 | 0.05 | -0.02 | -0.05 | -0.16 |
| Normalized Basic EPS | -0.04 | 0.02 | 0.02 | 0.00 | -0.08 |
| EPS Diluted | -0.07 | 0.05 | -0.02 | -0.05 | -0.16 |
| Normalized Diluted EPS | -0.04 | 0.02 | 0.02 | 0.00 | -0.08 |
| Average Basic Shares Outstanding | 307.69M | 306.14M | 304.69M | 303.77M | 302.90M |
| Average Diluted Shares Outstanding | 307.69M | 306.14M | 304.69M | 303.77M | 302.90M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |